Ensysce Biosciences Expands Investor Outreach at Family Office Summit
Ensysce Biosciences announced an expansion of its global investor and strategic outreach efforts at the Family Office Summit in Dubai.
Stocks · News reference
Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028
Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in private financing consisting of $21.5
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.
8-K filing — Ensysce Biosciences, Inc. (ENSC)
Filed: 2026-09-29 AccNo: 0001493152-26-044802 Size: 225 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study
~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc.